Prostate Cancer Treatment and Research

Longitudinal single-cell RNA sequencing of a neuroendocrine transdifferentiation model reveals transcriptional reprogramming in treatment-induced neuroendocrine prostate cancer

This study uses longitudinal scRNA-seq to track neuroendocrine transdifferentiation in a prostate cancer model, identifying transcriptional changes and key regulators during treatment-induced NEPC progression.

Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

Spatial epigenomics reveals ancestry-associated regulatory states linked to aggressive prostate cancer biology

The paper identifies population-associated differences in chromatin regulation in prostate cancer, linking reduced CTCF accessibility to aggressive tumor biology in Black men.

cBAF drives AR-V7 expression through regulation of transcriptional termination in castration-resistant prostate cancer

This study identifies cBAF as a regulator of AR-V7 expression through chromatin-mediated transcriptional termination in CRPC.

Targeting TMPRSS2-ERG Fusion-Driven Prostate Cancer using Novel HBS-α-Helicomimics

This study designs and evaluates HBS-constrained alpha-helicomimics targeting ERG-DNA interfaces in TMPRSS2-ERG fusion-driven prostate cancer, showing reduced tumor growth and ERG activity in preclinical models.

A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate Cancer.

This study identifies mTOR signaling as a therapeutic target in AXL-deficient advanced prostate cancer through kinase inhibitor screening and functional analysis.

A low-androgen environment sustains redox-active sGC states required to restrain castration-resistant prostate cancer growth via elevated cGMP levels

This study shows that a low-androgen environment maintains redox-active sGC states, enhancing riociguat efficacy in castration-resistant prostate cancer by increasing cGMP levels.

An androgen-derived transcriptional state reveals signaling and mitochondrial vulnerabilities in cancer

The paper identifies an androgen-derived transcriptional state in cancer cells and links it to drug resistance and mitochondrial vulnerabilities.

Proteomic Characterization of Prostate Cancer Bone Metastasis Subtypes Defines Progressive Remodeling States of the Bone-Tumor Microenvironment

This study identifies proteomic signatures of prostate cancer bone metastasis subtypes, revealing distinct molecular states of bone-tumor microenvironment remodeling.

An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation.

This study uses an immunocompetent mouse model to show that Degarelix-induced chemical castration suppresses prostate cancer tumor growth initially but leads to acquired resistance over time.

Immune determinants of leuprolide-associated cardiovascular risk in prostate cancer

This study identifies immune programs linked to leuprolide-associated cardiovascular risk in prostate cancer patients through spatial transcriptomic and immune-stromal profiling.

Establishment and characterization of LNCaP-TR-BoM, a bone metastasis-derived prostate cancer cell line with an intermediate AR-attenuated phenotype

This paper establishes and characterizes LNCaP-TR-BoM, a bone metastasis-derived prostate cancer cell line with an intermediate AR-attenuated phenotype, showing transcriptomic and functional similarities to metastatic castration-resistant prostate cancer.

Dual inhibition of p38α MAPK and Casein kinase δ/ϵ as a novel treatment strategy for AR-independent and taxane-resistant advanced prostate cancer

This paper demonstrates that TAK-715, a dual inhibitor of p38α MAPK and casein kinase δ/ϵ, effectively treats taxane-resistant and aggressive prostate cancer by targeting cancer stemness and mitochondrial dysfunction.

An FEV-Associated Metastasis-Initiating-Like State Linked to Tumor Cell Plasticity and Immune Niche Remodeling in Prostate Cancer

The paper identifies a metastasis-initiating-like state in prostate cancer linked to FEV, tumor plasticity, and immune niche remodeling through integrated multi-omics analysis.

Profiling crystal engineered ligands for targeting treatment resistant androgen receptors

This study develops and evaluates crystal-engineered ligands (CBs) for targeting treatment-resistant androgen receptors in prostate cancer, showing their potential as novel therapeutic agents.

Neuroendocrine prostate cancer converges on a fetal pulmonary neuroendocrine-like program

This study identifies NEPC as a malignant state converging on a fetal pulmonary neuroendocrine-like program and identifies ASCL1-linked regulatory targets.

Rewiring Oncogenic Transcriptional Complexes with Domain-ALTerAtion Chimeras (DALTACs) in Prostate Cancer

A bifunctional AR–p300/CBP molecule, DALTAC-1, forces a non-native contact between AR and p300 domains, silences AR enhancers and regresses AR-driven prostate tumors in mice while sparing AR-negative lines.

AR-V7 Utilizes a Noncanonical Nuclear Localization Signal to Sustain Androgen-Independent Nuclear Import and Signaling

This study identifies a noncanonical nuclear localization signal in AR-V7 that enables androgen-independent nuclear import and transcriptional activity, revealing distinct vulnerabilities for targeting AR-V7 signaling.

Amyloid precursor protein. An Achilles heel to exploit in the treatment of prostate cancer

This study shows that amyloid precursor protein (APP) is upregulated in prostate tumors and critical for cancer cell survival through interactions with androgen and IGF-I signaling, suggesting potential for repurposing AD drugs in prostate cancer treatment.

An integrated, transcript-resolution atlas of prostate cancer progression unmasks associations with oncogenic pathways

A transcript-resolution prostate cancer atlas, built by uniformly reprocessing public RNA-seq cohorts, links isoform switches in cancer genes to oncogenic pathway activity and some to CRPC survival.

SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer

This study identifies SRPK1 as a key regulator of docetaxel resistance in prostate cancer by modulating splicing and apoptosis pathways.

Dynamics of circulating tumor cell subsets defined by PSMA and EpCAM predict survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617

The paper assesses CTC subset dynamics in mCRPC patients treated with 177Lu-PSMA-617 and finds that changes in PSMA and EpCAM-expressing CTCs correlate with survival outcomes.

Ancestry-Dependent Immunologic and Prognostic Effects Characterize the Prostate Cancer Urinary Proteome

The paper quantifies urinary proteome differences between Black and White prostate cancer patients, finding immune pathway dysregulation and aggressive cancer features in Black patients after controlling for age, PSA, and cISUP.

Pharmacologic Targeting of ZNF281 Suppresses Metastatic Prostate Cancer Beyond Androgen Receptor Dependence

This study identifies ZNF281 as a driver of metastatic prostate cancer and shows that targeting it with a novel inhibitor suppresses tumor growth and metastasis in multiple models.

A patient-centric therapeutic paradigm uncouples prostate cancer suppression from systemic metabolic collapse

This paper identifies metabolic dysregulation caused by abiraterone in prostate cancer patients and develops Lifehug-9892 to suppress tumors while preserving systemic metabolic health.

Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2

This study identifies CDK2 as a therapeutic target in castration-resistant prostate cancer and shows that combining CDK2 inhibitors with AR inhibitors enhances efficacy without harming normal cells.

A Spatiotemporal Atlas of the Androgen Receptor Proximal Interactome

The paper constructs a spatiotemporal atlas of the androgen receptor proximal interactome using PL-qMS, identifying 4,751 AR-PIPs and revealing a retromer-AR-TMF1 axis involved in androgen-regulated transcription.

A generalized resource-allocation growth law reveals mechanisms of differential responses to intermittent androgen deprivation therapy in prostate cancer

This paper develops a generalized resource-allocation growth law to model prostate cancer responses to intermittent androgen deprivation therapy, showing it predicts treatment outcomes and adapts to different schedules.

Extracellular matrix regulates lineage plasticity in prostate cancer through YAP/TEAD

Loss of extracellular matrix-integrin signaling switches off YAP/TEAD and lets prostate adenocarcinoma organoids turn neuroendocrine; LATS inhibition reverses it, and combined YAP, NOTCH and AR inhibition fully reprograms them.

Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations with Race and Prostate Cancer Outcomes

The paper examines subclonal complete loss of CDKN1B in prostate cancer, finding higher prevalence in African American individuals and associations with worse outcomes.